APLM Apollomics Inc. Class A Ordinary Shares

USD 0.23 0.00 0.921457
Icon

Apollomics Inc. Class A Ordinary Shares (APLM) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.23

+0.00 (+0.92)%

USD 0.02B

0.02B

USD 3.50(+1,421.74%)

N/A

Icon

APLM

Apollomics Inc. Class A Ordinary Shares (USD)
COMMON STOCK | NSD
USD 0.23
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.02B

N/A

USD 0.23

Apollomics Inc. Class A Ordinary Shares (APLM) Stock Forecast

Show ratings and price targets of :
USD 3.50
(+1,421.74%)

Based on the Apollomics Inc. Class A Ordinary Shares stock forecast from 1 analysts, the average analyst target price for Apollomics Inc. Class A Ordinary Shares is USD 3.50 over the next 12 months. Apollomics Inc. Class A Ordinary Shares’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apollomics Inc. Class A Ordinary Shares is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Apollomics Inc. Class A Ordinary Shares’s stock price was USD 0.23. Apollomics Inc. Class A Ordinary Shares’s stock price has changed by +13.81% over the past week, +11.92% over the past month and -95.91% over the last year.

No recent analyst target price found for Apollomics Inc. Class A Ordinary Shares
No recent average analyst rating found for Apollomics Inc. Class A Ordinary Shares

Company Overview Apollomics Inc. Class A Ordinary Shares

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), a...Read More

989 East Hillsdale Blvd, Foster City, CA, United States, 94404

45

December

USD

USA

Adjusted Closing Price for Apollomics Inc. Class A Ordinary Shares (APLM)

Loading...

Unadjusted Closing Price for Apollomics Inc. Class A Ordinary Shares (APLM)

Loading...

Share Trading Volume for Apollomics Inc. Class A Ordinary Shares Shares

Loading...

Compare Performance of Apollomics Inc. Class A Ordinary Shares Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for APLM

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Apollomics Inc. Class A Ordinary Shares (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -0.25 (-0.05%) USD127.00B 31.94 20.00

ETFs Containing APLM

Symbol Name APLM's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Apollomics Inc. Class A Ordinary Shares (APLM) Stock

Based on ratings from 1 analysts Apollomics Inc. Class A Ordinary Shares's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and hold ratings.

Unfortunately we do not have enough data on APLM's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for APLM is USD 3.50 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 2.

Unfortunately we do not have enough data on APLM's stock to indicate if its overvalued.

The last closing price of APLM's stock was USD 0.23.

The most recent market capitalization for APLM is USD 0.02B.

Based on targets from 1 analysts, the average taret price for APLM is projected at USD 3.50 over the next 12 months. This means that APLM's stock price may go up by +1,421.74% over the next 12 months.

We can't find any ETFs which contains Apollomics Inc. Class A Ordinary Shares's stock.

As per our most recent records Apollomics Inc. Class A Ordinary Shares has 45 Employees.

Apollomics Inc. Class A Ordinary Shares's registered address is 989 East Hillsdale Blvd, Foster City, CA, United States, 94404. You can get more information about it from Apollomics Inc. Class A Ordinary Shares's website at https://www.apollomicsinc.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...